In this study, we investigated whether the 313 variant–based PRS for breast cancer is associated with contralateral breast cancer risk among women of European ancestry with pathogenic variants in BRCA1/2 and explored the implications for contralateral breast cancer risk prediction for these women. Here, BRCA1 is linked to breast cancer.